Company Filing History:
1 out of 1 
1 out of 3 
1 out of 4 
Years Active: 2017-2025
Title: Ramón Mangues Bafalluy: Innovator in Therapeutic Nanoconjugates
Introduction
Ramón Mangues Bafalluy is a prominent inventor based in Barcelona, Spain. He has made significant contributions to the field of therapeutic nanoconjugates, holding 2 patents that focus on innovative methods for targeted drug delivery. His work is pivotal in advancing therapeutic applications that can improve patient outcomes.
Latest Patents
One of his latest patents is titled "Therapeutic nanoconjugates and uses thereof." This invention relates to nanostructured conjugates, specifically nanostructured fusion proteins designed for the selective delivery of therapeutic agents to specific cell and tissue types. It also encompasses nanoparticles that include such nanostructured proteins and their therapeutic applications. Another notable patent is "Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells." This patent provides conjugates that include a targeting moiety specific for CXCR4, based on a polyphemusin-derived peptide, along with a therapeutic or imaging agent. The methods and reagents described are essential for the targeted delivery of therapeutic molecules to CXCR4+ cells.
Career Highlights
Throughout his career, Ramón has worked with esteemed institutions such as Universitat Autonoma de Barcelona and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. His research has significantly impacted the field of nanomedicine, particularly in the development of targeted therapies.
Collaborations
Ramón has collaborated with various professionals in his field, including Ugutz Unzueta Elorza. These collaborations have further enriched his research and contributed to the advancement of therapeutic innovations.
Conclusion
In summary, Ramón Mangues Bafalluy is a distinguished inventor whose work in therapeutic nanoconjugates is paving the way for more effective medical treatments. His patents reflect a commitment to improving targeted drug delivery systems, which hold great promise for future therapeutic applications.